XML 38 R29.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
| For the Three Months Ended September 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 842.0 |  |  | $ | 280.4 |  |  | $ | 1,122.4 |  |  | $ | 842.1 |  |  | $ | 247.9 |  |  | $ | 1,090.0 |
Interferon* | 360.3 |  |  | 169.7 |  |  | 530.0 |  |  | 421.5 |  |  | 168.6 |  |  | 590.1 |
TYSABRI | 263.0 |  |  | 220.6 |  |  | 483.6 |  |  | 253.0 |  |  | 217.2 |  |  | 470.2 |
FAMPYRA | — |  |  | 24.2 |  |  | 24.2 |  |  | — |  |  | 22.5 |  |  | 22.5 |
Subtotal: MS product revenues | 1,465.3 |  |  | 694.9 |  |  | 2,160.2 |  |  | 1,516.6 |  |  | 656.2 |  |  | 2,172.8 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 236.7 |  |  | 310.4 |  |  | 547.1 |  |  | 223.9 |  |  | 243.8 |  |  | 467.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 115.9 |  |  | 115.9 |  |  | — |  |  | 123.4 |  |  | 123.4 |
IMRALDI | — |  |  | 49.3 |  |  | 49.3 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 18.4 |  |  | 18.4 |  |  | — |  |  | 11.4 |  |  | 11.4 |
Subtotal: Biosimilar product revenues | — |  |  | 183.6 |  |  | 183.6 |  |  | — |  |  | 134.8 |  |  | 134.8 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 3.8 |  |  | 3.8 |  |  | — |  |  | 4.8 |  |  | 4.8 |
Total product revenues | $ | 1,702.0 |  |  | $ | 1,192.7 |  |  | $ | 2,894.7 |  |  | $ | 1,740.5 |  |  | $ | 1,039.6 |  |  | $ | 2,780.1 |
*Interferon includes AVONEX and PLEGRIDY.
| For the Nine Months Ended September 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 2,429.5 |  |  | $ | 841.9 |  |  | $ | 3,271.4 |  |  | $ | 2,396.8 |  |  | $ | 766.9 |  |  | $ | 3,163.7 |
Interferon* | 1,067.3 |  |  | 518.0 |  |  | 1,585.3 |  |  | 1,237.5 |  |  | 528.4 |  |  | 1,765.9 |
TYSABRI | 772.3 |  |  | 647.0 |  |  | 1,419.3 |  |  | 768.2 |  |  | 631.3 |  |  | 1,399.5 |
FAMPYRA | — |  |  | 71.2 |  |  | 71.2 |  |  | — |  |  | 69.9 |  |  | 69.9 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |
Subtotal: MS product revenues | 4,269.1 |  |  | 2,078.1 |  |  | 6,347.2 |  |  | 4,402.5 |  |  | 1,997.9 |  |  | 6,400.4 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 690.6 |  |  | 863.2 |  |  | 1,553.8 |  |  | 617.8 |  |  | 636.5 |  |  | 1,254.3 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 360.2 |  |  | 360.2 |  |  | — |  |  | 359.9 |  |  | 359.9 |
IMRALDI | — |  |  | 132.3 |  |  | 132.3 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 49.9 |  |  | 49.9 |  |  | — |  |  | 29.2 |  |  | 29.2 |
Subtotal: Biosimilar product revenues | — |  |  | 542.4 |  |  | 542.4 |  |  | — |  |  | 389.1 |  |  | 389.1 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 11.6 |  |  | 11.6 |  |  | — |  |  | 17.3 |  |  | 17.3 |
Total product revenues | $ | 4,959.7 |  |  | $ | 3,495.3 |  |  | $ | 8,455.0 |  |  | $ | 5,020.3 |  |  | $ | 3,040.8 |  |  | $ | 8,061.1 |
*Interferon includes AVONEX and PLEGRIDY.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2018 | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 480.3 |  |  | 2,149.7 |  |  | 16.1 |  |  | 2,646.1 |
Adjustments relating to prior years | (0.4 | ) |  | (46.7 | ) |  | 4.6 |  |  | (42.5 | )
Payments/credits relating to sales in current year | (349.3 | ) |  | (1,510.0 | ) |  | (0.7 | ) |  | (1,860.0 | )
Payments/credits relating to sales in prior years | (129.3 | ) |  | (564.4 | ) |  | (15.4 | ) |  | (709.1 | )
Balance, as of September 30, 2019 | $ | 129.1 |  |  | $ | 917.4 |  |  | $ | 39.3 |  |  | $ | 1,085.8 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of September 30, 2019 |  | As of December 31, 2018
Reduction of accounts receivable, net | $ | 201.6 |  |  | $ | 176.6 |
Component of accrued expenses and other | 884.2 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,085.8 |  |  | $ | 1,051.3 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA | $ | 393.2 |  |  | $ | 358.0 |  |  | $ | 1,161.2 |  |  | $ | 1,066.6 |
Other revenues from anti-CD20 therapeutic programs | 202.6 |  |  | 153.7 |  |  | 528.4 |  |  | 378.7 |
Total revenues from anti-CD20 therapeutic programs | $ | 595.8 |  |  | $ | 511.7 |  |  | $ | 1,689.6 |  |  | $ | 1,445.3 |
Other revenues | Other revenues are summarized as follows:
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Revenues from collaborative and other relationships: |  |  |  |  |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie | $ | 0.3 |  |  | $ | (0.7 | ) |  | $ | (0.2 | ) |  | $ | (7.9 | )
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis | 12.9 |  |  | 48.1 |  |  | 89.9 |  |  | 80.7 |
Other royalty and corporate revenues: |  |  |  |  |  |  |  |  |
Royalty | 3.3 |  |  | 7.9 |  |  | 9.9 |  |  | 35.8 |
Other corporate | 93.1 |  |  | 91.9 |  |  | 462.4 |  |  | 311.6 |
Total other revenues | $ | 109.6 |  |  | $ | 147.2 |  |  | $ | 562.0 |  |  | $ | 420.2 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration